Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Immunome stock rises after insider purchase | 1 | Seeking Alpha | ||
Di | Immunome-CTO Philip Tsai kauft Aktien im Wert von 103.566 US-Dollar | 2 | Investing.com Deutsch | ||
Di | Immunome-Direktor Jean Jacques Bienaime erwirbt Aktien im Wert von 57.470 US-Dollar | 2 | Investing.com Deutsch | ||
21.03. | Immunome (NASDAQ:IMNM) Receives "Outperform" Rating from Wedbush | 1 | MarketBeat | ||
IMMUNOME Aktie jetzt für 0€ handeln | |||||
21.03. | Guggenheim Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock Price | 1 | MarketBeat | ||
20.03. | Immunome (NASDAQ:IMNM) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPS | 1 | MarketBeat | ||
20.03. | Immunome stock target cut to $25 by Guggenheim | 1 | Investing.com | ||
19.03. | Immunome Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
19.03. | Immunome GAAP EPS of -$5.00 misses by $0.62, revenue of $9.04M misses by $0.37M | 1 | Seeking Alpha | ||
19.03. | Immunome Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
19.03. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
30.01. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
30.01. | Immunome-Aktie stürzt nach Preisfestsetzung für öffentliches Angebot ab | 2 | Investing.com Deutsch | ||
30.01. | Immunome stock tumbles after public offering pricing | 1 | Investing.com | ||
29.01. | Immunome plans to commence underwritten public offering | 4 | Seeking Alpha | ||
29.01. | Immunome kündigt Aktienemission im Wert von 125 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
29.01. | Immunome announces $125 million stock offering | 3 | Investing.com | ||
23.01. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
07.01. | Hummingbird Bioscience signs license agreement with Immunome | 2 | Seeking Alpha | ||
01.01. | Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 10.1% in December | 1 | MarketBeat |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 28,740 | +0,31 % | Moderna-Aktie leicht im Minus (29,9070 €) | Der Anteilsschein von Moderna notiert heute ein wenig leichter. Der jüngste Kurs betrug 32,24 US-Dollar. Für der Anteilsschein von Moderna steht gegenwärtig ein Abschlag von 4,13 Prozent zu Buche. Die... ► Artikel lesen | |
CRISPR THERAPEUTICS | 34,100 | 0,00 % | Crispr Therapeutics Aktie: Verliert ihren Kurs? | Der Austritt des operativen Geschäftsführers beim Gentherapie-Unternehmen beunruhigt Investoren und wirft Fragen zur Projektkontinuität im wettbewerbsintensiven Biotech-Sektor auf. Die Finanzmärkte... ► Artikel lesen | |
INFLARX | 1,110 | +1,37 % | Guggenheim Raises InflaRx (NASDAQ:IFRX) Price Target to $10.00 | ||
TEMPUS AI | 47,480 | -8,64 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? | ||
XOMA ROYALTY | 19,200 | +2,13 % | The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts | ||
OCULAR THERAPEUTIX | 7,376 | +5,55 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
MACROGENICS | 1,205 | +3,97 % | MacroGenics stock target cut to $2 at H.C. Wainwright | ||
CORCEPT THERAPEUTICS | 50,18 | -0,52 % | Corcept Therapeutics-Präsident Sean Maduck verkauft Aktien im Wert von 102.804 US-Dollar | ||
VANDA PHARMACEUTICALS | 4,260 | -1,39 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results | Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023
Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023
Full year 2024... ► Artikel lesen | |
ROIVANT SCIENCES | 9,538 | -1,47 % | Roivant Sciences: Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
ULTRAGENYX | 34,200 | -2,29 % | Ultragenyx Is Uniquely Positioned In Long Term, Remains On JPMorgan's Focus List | ||
ADVERUM BIOTECHNOLOGIES | 4,520 | -1,74 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD | Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS... ► Artikel lesen | |
ANNOVIS BIO | 1,546 | +1,05 % | Annovis Bio Inc.: Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE | MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
AMNEAL PHARMACEUTICALS | 7,550 | -1,31 % | Amneal Reports Third Quarter 2024 Financial Results | BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2024.
"Q3 was... ► Artikel lesen | |
4D MOLECULAR THERAPEUTICS | 3,630 | +1,97 % | 4D Molecular Therapeutics Inc Aktie: Kommt die Trendwende jetzt? | Biotech-Unternehmen beginnt Phase-3-Studie zur Gentherapie gegen Makuladegeneration trotz erheblicher Kursverluste der FDMT-Aktie im vergangenen Jahr. 4D Molecular Therapeutics hat am 10. März 2025... ► Artikel lesen |